US20020004232A1 - Tumor suppressor gene del-27 - Google Patents

Tumor suppressor gene del-27 Download PDF

Info

Publication number
US20020004232A1
US20020004232A1 US09/771,404 US77140401A US2002004232A1 US 20020004232 A1 US20020004232 A1 US 20020004232A1 US 77140401 A US77140401 A US 77140401A US 2002004232 A1 US2002004232 A1 US 2002004232A1
Authority
US
United States
Prior art keywords
leu
pro
ser
lys
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/771,404
Other languages
English (en)
Inventor
Ilse Wieland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US09/771,404 priority Critical patent/US20020004232A1/en
Publication of US20020004232A1 publication Critical patent/US20020004232A1/en
Priority to US10/263,316 priority patent/US20030059825A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors

Definitions

  • the present invention relates to the new tumor suppressor gene del-27, the protein coded thereby, and their use for diagnostics and therapeutics, especially in the field of cancer.
  • the invention relates to the diagnosis of the lack of tumor suppressor gene del-27 in mammalian, especially in tumor, cells and gene therapy methods to restore del-27 and its functions in mammalian cells, especially in tumor cells.
  • Tumor suppressor genes are typically thought of as genes whose expression is reduced or lost in cancer cells (Knudson, Proc. Natl. Acad. Sci. USA 19 (1993) 10914-10921). The lack of expression results from mutations in the genes encoding their proteins. Since these proteins are believed to suppress cell growth and thereby act as negative growth regulators, loss of their expression in tumor cells leads to the increased cell proliferation observed and contributes to malignant transformation. As negative growth regulators, tumor suppressor gene products are likely to have also normal functions critical to the development of differentiated tissues. In this respect, tumor suppressor genes may have an important role in the growth arrest necessary for the onset of cellular differentiation as growth regulation is a normal feature of development and differentiation. An overview of tumor suppressor genes is given by, e.g., Gutmann, D. H., Int. J. Dev. Biol. 39 (1995) 895-907.
  • Inactivation of tumor suppressor genes appears to be a predominant genetic event in the genesis and progression of many tumors. In normal cells, these genes are thought to be involved in the regulation of cell proliferation and differentiation (Fearon, E., and Vogelstein, B., Cell 61 (1990) 759-767). Inactivating mutations and deletions of tumor suppressor genes may therefore release normal growth constraints and may result in the development or progression of tumor cells.
  • a genomic region that contains a putative tumor suppressor gene can be identified by frequent loss of heterozygosity (LOH) of the normal allele with the remaining allele beeing presumably non-functional in the tumor cells (Fearon, E., and Vogelstein, B., Cell 61 (1990) 759-767).
  • LHO heterozygosity
  • del-27 was isolated by genomic difference cloning and is homozygously deleted in a lung carcinoma cell line supporting its close linkage to a novel putative tumor suppressor gene (Wieland, I., Proc. Natl. Acad. Sci. USA 87 (1992) 2720-2724). However, no cDNA coding for a tumor suppressor gene was described therein.
  • the invention comprises an isolated nucleic acid molecule (del-27) having the nucleic acid sequence SEQ ID NO:1.
  • the invention also comprises an isolated nucleic acid molecule that hybridizes under stringent conditions with each of nucleic acid fragments 477-819, 820-3069 and 3070-3137 of SEQ ID NO:1, or the complementary nucleic acids therto, and which is capable of suppressing cell proliferation.
  • the invention further comprises a recombinant polypeptide which suppresses cell proliferation and is selected from the group consisting of
  • polypeptides according to the invention which are described immediately above, can be defined by their DNA sequences as well as by the amino acid sequence derived therefrom.
  • the del-27 polypeptide can occur in natural allelic variations which differ from individual to individual. Such variations of the amino acids are usually amino acid substitutions. However, they may also be deletions, insertions or additions of amino acids to the total sequence.
  • the del-27 protein according to the invention can be in glycosylated or non-glycosylated form depending on the cell type in which it is expressed and the extent to which it is expressed in a particular cell. Polypeptides with tumor-suppressive activity can easily be identified by a tumor growth inhibition assay using carcinoma cells expressing said polypeptides and measuring the proliferation capacity and apoptosis in relation to carcinoma cells not expressing said polypeptides.
  • Polypeptide with del-27 activity or del-27 means also proteins with minor amino acid variations but with substantially the same del-27 activity. Substantially the same means that the activities are of the same biological properties and the polypeptides show preferably at least 75% homology in amino acid sequence. More preferably, the amino acid sequences are at least 90% identical.
  • nucleic acid molecule denotes a polynucleotide which can be, for example, a DNA, RNA, or derivatized active DNA or RNA. DNA and/or RNA molecules are preferred, however.
  • hybridize under stringent conditions means that two nucleic acid fragments are capable of hybridization to one another under standard hybridization conditions described in Sambrook et al., “Expression of cloned genes in E. coli ” in Molecular Cloning: A laboratory manual (1989) Cold Spring Harbor Laboratory Press, New York, USA, 9.47-9.62 and 11.45 - 11.61.
  • “stringent conditions” as used herein refer to hybridization in 6.0 ⁇ SSC at about 45° C., followed by a wash of 2.0 ⁇ SSC at 50° C.
  • the salt concentration in the wash step can be selected, for example from about 2.0 ⁇ SSC at 50° C., for low stringency, to about 0.2 ⁇ SSC at 50° C., for high stringency.
  • the temperature in the wash step can be increased from low stringency conditions at room temperatures, about 22° C., to high stringency conditions at about 65° C.
  • isolated refers to a nucleic acid or polypeptide having del-27 activity and being substantially free of cellular material or culture medium, when produced by recombinant DNA techniques, or being substantially free of chemical precursors or other chemicals, when synthesized chemically.
  • An isolated nucleic acid is preferably free of sequences which naturally flank the nucleic acid (i.e. sequences located at the 5′ and the 3′ ends of the nucleic acid) in the organism from which the nucleic acid is derived.
  • del-27 can be purified after recombinant production by affinity chromatography using known protein purification techniques, including immunoprecipitation, gel filtration, ion exchange chromatography, chromatofocussing, isoelectric focussing, selective precipitation, electrophoresis, and the like.
  • the polypeptides according to the invention can be produced by recombinant means or synthetically.
  • Non-glycosylated del-27 polypeptide is obtained when it is produced recombinantly in prokaryotes.
  • nucleic acid sequences provided by the invention it is possible to search for the del-27 gene or its variants in genomes of any desired cells (e.g. apart from human cells, also in cells of other mammals), to identify these and to isolate the desired gene coding for the del-27 protein.
  • Such processes and suitable hybridization conditions are known to a person skilled in the art and are described, for example in Sambrook, J., et al., “Expression of cloned genes in E.
  • del-27 derivatives can, for example, be modified in individual or several amino acids by substitution, deletion or addition.
  • the derivatization can, for example, be carried out by means of site directed mutagenesis. Such variations can be easily carried out by a person skilled in the art (J. Sambrook, B. D. Hames, loc. cit.). It merely has to be ensured by means of the below-mentioned tumor cell growth inhibition assay that the characteristic properties of del-27 are preserved.
  • the invention therefore is also directed to del-27 polypeptides that are the products of a prokaryotic or eukaryotic expression of an exogenous DNA.
  • the proteins according to the invention can be obtained in a reproducible manner and in large amounts.
  • the nucleic acid sequence is integrated into suitable expression vectors, according to methods familiar to a person skilled in the art.
  • suitable expression vectors preferably contains a regulatable/inducible promoter. These recombinant vectors are then introduced for the expression into suitable host cells such as, e.g., E.
  • coli as a prokaryotic host cell or Saccharomyces cerevisiae, Terato carcinoma cell line PA-I sc 9117 (Büittner et al., Mol. Cell. Biol. 11 (1991) 3573-3583), insect cells, CHO or COS cells as eukaryotic host cells, and the transformed or transduced host cells are cultured under conditions which allow an expression of the heterologous gene.
  • the isolation of the protein can be carried out according to known methods from the host cell or from the culture supernatant of the host cell. Such methods are described for example by Ausubel I., Frederick M., Current Protocols in Mol. Biol. (1992), John Wiley and Sons, New York. Also in vitro reactivation of the protein may be necessary if it is not found in soluble form in the cell culture.
  • the invention further comprises recombinant expression vectors which are suitable for the expression of del-27 and the above-described related proteins, recombinant host cells transfected with such expression vectors, as well as a process for the recombinant production of a protein which is coded by a tumor suppressor gene del-27.
  • the invention further comprises a method for detecting a nucleic acid molecule of tumor suppressor gene del-27, comprising incubating a sample (e.g. body fluids such as blood, cell lysates) with the isolated nucleic acid molecule according to the invention and determining hybridization under stringent conditions of said isolated nucleic acid molecule to a target nucleic acid molecule as a determination of presence of a nucleic acid molecule which is the del-27 tumor suppressor gene.
  • a sample e.g. body fluids such as blood, cell lysates
  • the invention further comprises a method for producing a protein which is capable of suppressing cell proliferation by expressing an exogenous DNA in prokaryotic or eukaryotic host cells and isolation of the desired protein, wherein the DNA
  • a) is coded by the DNA sequence shown in SEQ ID NO:1, or
  • b) is coded by DNA sequence which hybridizes under stringent conditions with each of the nucleic acid fragments 477-819, 820-3069 and 3070-3137 of SEQ ID NO:1, or the complementary DNA sequences, thereto, or
  • c) is coded by a DNA sequence which, if there was no degeneracy of the genetic code, would hybridize under stringent conditions with any of the sequences defined in a) or b) above.
  • the invention further comprises an isolated protein according to the invention which is encoded by a nucleic acid molecule having the nucleotide sequence set forth in SEQ ID NO:1.
  • the present invention relates to the cloning and characterization of a tumor suppressor gene which is especially characterized as a tumor progression gene.
  • the functional loss of the tumor suppressor gene according to the invention releases contact inhibition and anchorage dependence in tumor cells. Therefore the loss of del-27 gene correlates with a more aggressive behavior of the tumor cells and also the potential of the formation of metastasis.
  • del-27 and its expression products can be used to inhibit tumor growth, preferably of sporadic tumors (in particular, lung and bladder carcinomas) in vivo, preferably by somatic gene therapy.
  • the observed tumor suppressive activity of the del-27 cDNA or products of it can be used to inhibt tumor growth of sporadic tumors (in particular in carcinomas such as lung and bladder carcinomas) in vivo by somatic gene therapy.
  • Phage pools containing 10 5 plaque forming units produced from normal human genomic libraries (Clontech, Cat.# HL1067J; Stratagene, Cat.# 946205) and human fetal and placental cDNA libraires (Clontech, Cat.# HL1065a and # HL1075b) were screened by the polymerase chain reaction (PCR). PCR conditions were as described in Wieland, I., and Böhm, M., Cancer Res. 54 (1994) 1772-1774. For plaque screening filter lifts were hybridized with 32p-labeled probes and washed under standard conditions as described in Sambrook, J., et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, N.Y.
  • Probe p13B produced, in addition to the strong hybridizing signal from the del-27 region on chromosome 5, weaker signals on genomic Southern blots.
  • probe p13B cross-hybridized with another chromosomal region in the human genome, a somatic cell hybrid panel was analysed (Wieland, I., et al., Proc. Natl. Acad. Sci. USA 87 (1992) 2720-2724). Cross-hybridizing signals were detected in somatic cell hybrids containing human chromosome 13.
  • U57368, MMU57368) encoding a putative transmembrane protein involved in contact inhibition and anchorage dependent growth.
  • the tumor suppressive activity of the del-27 cDNA can be tested by introduction of either the entire coding region or parts of the coding region of the del-27 cDNA into carcinoma cells:
  • the entire coding region or in frame parts of the coding region are cloned into the tetracycline-inducible expression vector pUHD10-3 (Gossen, M., and Bujard, H., Proc. Natl. Acad. Sci. USA 89 (1992) 5547-5551). Together with a selection marker the different constructs are then electroporated into carcinoma cells containing the rtTa-gene on plasmid pUHD172-1neo (Gossen, M., et al., Science 268 (1995) 1766-1769). In selected cell clones expression of the del-27 cDNA is induced by treatment of the cells with tetracycline or doxycycline.
  • tumor suppressive activity of the del-27 cDNA constructs are determined by measuring the proliferative capacity and apoptosis of induced cells compared to non-induced cells.
  • the generated carcinoma cells are further investigated in an in vivo mouse model. Cells are injected into immune-deficient mice. Expression of the del-27 cDNA constructs in the carcinoma cells is induced by tetracycline when small tumor nodules are apparent. Tumor suppression (tumor growth inhibition, tumor regression) is monitored in the induced and non-induced state.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
US09/771,404 1998-02-26 2001-01-26 Tumor suppressor gene del-27 Abandoned US20020004232A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US09/771,404 US20020004232A1 (en) 1998-02-26 2001-01-26 Tumor suppressor gene del-27
US10/263,316 US20030059825A1 (en) 1998-02-26 2002-10-03 Tumor suppressor gene del-27

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP98103334A EP0943682A1 (de) 1998-02-26 1998-02-26 Tumor-Suppressor Gen Del-27 und das dadurch kodierte Protein, Verfahren zu deren Herstellung und Nutzung
EP98103334.3 1998-02-26
US25594799A 1999-02-23 1999-02-23
US09/771,404 US20020004232A1 (en) 1998-02-26 2001-01-26 Tumor suppressor gene del-27

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US25594799A Continuation 1998-02-26 1999-02-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/263,316 Continuation US20030059825A1 (en) 1998-02-26 2002-10-03 Tumor suppressor gene del-27

Publications (1)

Publication Number Publication Date
US20020004232A1 true US20020004232A1 (en) 2002-01-10

Family

ID=8231478

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/771,404 Abandoned US20020004232A1 (en) 1998-02-26 2001-01-26 Tumor suppressor gene del-27
US10/263,316 Abandoned US20030059825A1 (en) 1998-02-26 2002-10-03 Tumor suppressor gene del-27

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/263,316 Abandoned US20030059825A1 (en) 1998-02-26 2002-10-03 Tumor suppressor gene del-27

Country Status (7)

Country Link
US (2) US20020004232A1 (de)
EP (2) EP0943682A1 (de)
JP (1) JP3503928B2 (de)
AT (1) ATE283357T1 (de)
AU (1) AU713469B2 (de)
CA (1) CA2261964C (de)
DE (1) DE69922071T2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0031276D0 (en) * 2000-12-21 2001-01-31 Inpharmatica Ltd Novel protein
US6461843B1 (en) * 2001-02-16 2002-10-08 Applera Corporation Isolated nucleic acid molecules encoding human enzyme proteins, and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889806A (en) * 1987-04-15 1989-12-26 Washington University Large DNA cloning system based on yeast artificial chromosomes
EP0784096A1 (de) * 1996-01-10 1997-07-16 Boehringer Mannheim Gmbh Verfahren zum Nachweis von Polymorphismus und Heterozygotieverlust in einem Lungentumor-Suppressor-Gen

Also Published As

Publication number Publication date
EP0939126B1 (de) 2004-11-24
US20030059825A1 (en) 2003-03-27
EP0943682A1 (de) 1999-09-22
JPH11276183A (ja) 1999-10-12
JP3503928B2 (ja) 2004-03-08
DE69922071T2 (de) 2005-12-15
AU713469B2 (en) 1999-12-02
CA2261964A1 (en) 1999-08-26
ATE283357T1 (de) 2004-12-15
EP0939126A1 (de) 1999-09-01
AU1842099A (en) 1999-09-09
DE69922071D1 (de) 2004-12-30
CA2261964C (en) 2002-10-15

Similar Documents

Publication Publication Date Title
Yasothornsrikul et al. viking: identification and characterization of a second type IV collagen in Drosophila
Thomas et al. The human collagen X gene. Complete primary translated sequence and chromosomal localization
Hasson et al. Mapping of unconventional myosins in mouse and human
US20040170994A1 (en) DNA sequences for human tumour suppressor genes
WO1999002653A1 (en) Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use
AU713814B2 (en) 3' UTR of the human prohibitin gene
US6323316B1 (en) Fibroblast growth factor receptor activating gene 1 and related compositions and methods
BENNETT et al. Isolation of the mouse homologue of BRCA1 and genetic mapping to mouse chromosome 11
Chen et al. Norrie disease gene: characterization of deletions and possible function
WO2000000607A1 (en) A nucleic acid encoding a retinoblastoma binding protein (rbp-7) and polymorphic markers associated with said nucleic acid
Larsen et al. The WFDC1 gene encoding ps20 localizes to 16q24, a region of LOH in multiple cancers
US6762291B1 (en) Insect p53 tumor suppressor genes and proteins
Law et al. The human ZBP-89 homolog, located at chromosome 3q21, represses gastrin gene expression
US5543303A (en) Recombinant myelomonocytic differentiation antigen CD14
US20020004232A1 (en) Tumor suppressor gene del-27
JP2552942B2 (ja) ヒトｂーＦＧＦ受容体遺伝子
US6350867B1 (en) Compositions and methods for enhancing osseous growth, repair and regeneration
JP3187113B2 (ja) 細胞増殖因子
EP0972832A1 (de) Neues Gen mit reduzierter Expression in metastatischen menschlichen Melanoma-Zellen und das dadurch kodierte Protein, Methoden zur Herstellung und Verwendung
AU706666B2 (en) Novel gene associated with suppression of tumor development
AU2004202848B2 (en) A nucleic acid encoding a retinoblastoma binding protein (RBP-7) and polymorphic markers associated with said nucleic acid
Tarlé et al. The human ZBP-89 homolog, located at Chromosome 3q21, represses gastrin gene expression
CA2300805A1 (en) Polypeptide having a gtpase regulator activity, nucleic acids coding therefor and their use in diagnostics and therapy

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION